Osteoclast inhibition in postmenopausal breast cancer: Is the evidence too strong to ignore?

Alison T. Stopeck

doi:10.1002/cncr.30678

Osteoclast inhibition in postmenopausal breast cancer: Is the evidence too strong to ignore?

Alison T. Stopeck

Cancer Center

Research output: Contribution to journal › Editorial › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	2392-2394
Number of pages	3
Journal	Cancer
Volume	123
Issue number	13
DOIs	https://doi.org/10.1002/cncr.30678
State	Published - Jul 1 2017

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/cncr.30678

Cite this

@article{8a860e6a5994402ebca4928ef6afb80e,

title = "Osteoclast inhibition in postmenopausal breast cancer: Is the evidence too strong to ignore?",

author = "Stopeck, {Alison T.}",

year = "2017",

month = jul,

day = "1",

doi = "10.1002/cncr.30678",

language = "English (US)",

volume = "123",

pages = "2392--2394",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "13",

}

TY - JOUR

T1 - Osteoclast inhibition in postmenopausal breast cancer

T2 - Is the evidence too strong to ignore?

AU - Stopeck, Alison T.

PY - 2017/7/1

Y1 - 2017/7/1

UR - http://www.scopus.com/inward/record.url?scp=85018986379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018986379&partnerID=8YFLogxK

U2 - 10.1002/cncr.30678

DO - 10.1002/cncr.30678

M3 - Editorial

C2 - 28464216

AN - SCOPUS:85018986379

SN - 0008-543X

VL - 123

SP - 2392

EP - 2394

JO - Cancer

JF - Cancer

IS - 13

ER -

Osteoclast inhibition in postmenopausal breast cancer: Is the evidence too strong to ignore?

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this